ARCHIVES

Tamoxfin Trial accrues 6,000, Problems with Minority accrual Remain

This article is from The Cancer Letter archive.

Vol. 19 No. 14 | April 2, 1993

Download PDF Visit The Full Archive

Related Articles

Varmus to NCAB: Budgetary “Haircuts” No Longer Sufficient to Cope With Fiscal Pressure

September 16, 2011

NIH Funds 11 New Grants In Women’s Health Research.

September 29, 2000

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

October 17, 2008

Study: Vismodegib Effective Where Surgery is Inappropriate

June 24, 2011

Administration Seeks Authorization Bill Repealing National Cancer Act, Other NIH Special Authorities

March 8, 1985

Dendritic Cell Vaccine May Boost Median Survival

March 25, 2011